AgingResearch.NewsJoin free

Ridaforolimus

Ridaforolimus has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 13, 2021: “TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer”.

InterventionRapamycin analogs

1 paper studies it1 more mentions it1 findingUpdated

PubChem

See all 2

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 6 trials, none about aging, 5 with no results posted
  • Funders: Congressionally Directed Medical Research Programs and 5 more
  • 1 of 1 finding with company ties
  • Animals1

What did studies of Ridaforolimus find?

1

Studies of Ridaforolimus measured 1 outcome; the most studied are hTERT expression (1 study).

hTERT expression

downin human cells1

1 study

  1. Ridaforolimus decreases hTERT expression in human cells (mTORC1 inhibition).

    “mTORC1 inhibition with rapamycin analog Ridaforolimus suppresses TRIM28 phosphorylation, hTERT expression, and cell viability.”

    CellsmTORC1 inhibition

    TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer

    Proceedings of the National Academy of Sciences of the United States of America

More on hTERT expression

Trial sponsors

Latest

Related